Form 4: Day One Biopharmaceuticals Director, John A. Josey, Reports Stock Option Grant

Director John A. Josey reports the acquisition of stock options in Day One Biopharmaceuticals, Inc.

Summary

• On May 23, 2024, John A. Josey, a director of Day One Biopharmaceuticals, Inc. (DAWN), reported the acquisition of stock options.
• The stock option grants him the right to buy 32,335 shares of common stock at an exercise price of $13.87.
• The options vest monthly, starting June 23, 2024, over a 12-month period, contingent upon continued service to the company.
• The options expire on May 22, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a routine disclosure of stock option grants. It's a positive sign that the director is incentivized, but it doesn't significantly alter the investment outlook.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded biopharmaceutical companies.
• The size of the grant is typical for a director at a company of Day One Biopharmaceuticals' size and stage of development.
• Comparable companies such as Relay Therapeutics and Black Diamond Therapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates